2022, Número 4
<< Anterior Siguiente >>
Rev Nefrol Dial Traspl 2022; 42 (4)
Enfermedad renal diabética no proteinúrica: Estado del arte
Rico Fontalvo J, Aroca-Martínez G, Daza-Arnedo R, Raad-Sarabia M, Torres JL, Pajaro-Galvis N, Uparella-Gulfo I, Porto-Corbacho D, Sarabia-Cannepa S, Ramos-Clason E
Idioma: Español
Referencias bibliográficas: 52
Paginas: 330-339
Archivo PDF: 246.59 Kb.
RESUMEN
La enfermedad renal diabética
(ERD) es una de las complicaciones
crónicas de mayor incidencia en la
diabetes mellitus, considerándose en
la actualidad un problema de salud
pública. Clásicamente se han descrito
5 estadios definidos por Mogensen en
1980 donde destaca la presencia de
albuminuria como marcador temprano
de compromiso renal. Sin embargo, en
los últimos años se ha documentado
un 20-30% de pacientes con ERD que
no cursan con albuminuria a pesar
de tener un compromiso de la tasa
de filtración glomerular. Este grupo
se ha llamado como ERD fenotipo
no albuminúrico. Se han descrito
varios fenotipos atípicos, siendo el
fenotipo no albuminúrico uno de
los más frecuentes de este grupo. A
continuación, realizamos una revisión
del fenotipo no albuminúrico de la
ERD, desde su fisiopatología hasta las
medidas terapéuticas que impactan
en la mortalidad y la progresión a
enfermedad renal terminal
REFERENCIAS (EN ESTE ARTÍCULO)
Whiting DR, Guariguata L, Weil C, Shaw J. IDFDiabetes Atlas: Global estimates of the prevalenceof diabetes for 2011 and 2030. Diabetes Res ClinPract. Published online 2011. doi: 10.1016/j.diabres.2011.10.029.
Forouhi NG, Wareham NJ. Epidemiology of diabetes.Med (United Kingdom). Published online 2019. doi:10.1016/j.mpmed.2018.10.004.
Chawla A, Chawla R, Jaggi S. Microvasular andmacrovascular complications in diabetes mellitus:Distinct or continuum? Indian J Endocrinol Metab.Published online 2016. doi:10.4103/2230-8210.183480.
De Boer IH, Rue TC, Hall YN, Heagerty PJ, WeissNS, Himmelfarb J. Temporal trends in the prevalenceof diabetic kidney disease in the United States. JAMA- J Am Med Assoc. Published online 2011. doi:10.1001/jama.2011.861.
Smyth S, Heron A. Diabetes and obesity: Thetwin epidemics. Nat Med. Published online 2006.doi:10.1038/nm0106-75.
Umanath K, Lewis JB. Update on Diabetic Nephropathy:Core Curriculum 2018. Am J Kidney Dis. Publishedonline 2018. doi: 10.1053/j.ajkd.2017.10.026.
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidneydisease: A report from an ADA consensus conference.Diabetes Care. Published online 2014. doi:10.2337/dc14-1296.
Mogensen CE, Christensen CK, Vittinghus E. Thestages in diabetic renal disease. With emphasis onthe stage of incipient diabetic nephropathy. Diabetes.Published online 1983. doi:10.2337/diab.32.2. s64.
Chen Y, Lee K, Ni Z, He JC. Diabetic Kidney Disease:Challenges, Advances, and Opportunities. Kidney Dis.Published online 2020. doi:10.1159/000506634.
A/L B Vasanth Rao VR, Tan SH, Candasamy M,Bhattamisra SK. Diabetic nephropathy: An updateon pathogenesis and drug development. DiabetesMetab Syndr Clin Res Rev. Published online 2019. doi:10.1016/j.dsx.2018.11.054.
Chawla V, Roshan B. Non-Proteinuric DiabeticNephropathy. Curr Diab Rep. Published online 2014.doi:10.1007/s11892-014-0529-6.
Perkins BA, Ficociello LH, Silva KH, FinkelsteinDM, Warram JH, Krolewski AS. Regression ofMicroalbuminuria in Type 1 Diabetes. N Engl J Med.Published online 2003. doi:10.1056/nejmoa021835.
Araki SI, Haneda M, Sugimoto T, et al. Factorsassociated with frequent remission of microalbuminuriain patients with type 2 diabetes. Diabetes. Publishedonline 2005. doi:10.2337/diabetes.54.10.2983.
Dwyer JP, Parving H-H, Hunsicker LG, RavidM, Remuzzi G, Lewis JB. Renal Dysfunction in thePresence of Normoalbuminuria in Type 2 Diabetes:Results from the DEMAND Study. Cardiorenal Med.Published online 2011. doi:10.1159/000333249.
Russo LM, Sandoval RM, McKee M, et al. The normalkidney filters nephrotic levels of albumin retrievedby proximal tubule cells: Retrieval is disrupted innephrotic states. Kidney Int. Published online 2007.doi:10.1038/sj.ki.5002041.
Nauta FL, Boertien WE, Bakker SJL, et al. Glomerularand tubular damage markers are elevated in patientswith diabetes. Diabetes Care. Published online 2011.doi:10.2337/dc10-1545.
Sugahara M, Pak WLW, Tanaka T, Tang SCW,Nangaku M. Update on diagnosis, pathophysiology,and management of diabetic kidney disease. Nephrology.Published online 2021. doi:10.1111/nep.13860.
Garg AX, Kiberd BA, Clark WF, Haynes RB, ClaseCM. Albuminuria and renal insufficiency prevalenceguides population screening: Results from theNHANES III. Kidney Int. Published online 2002.doi:10.1046/j.1523-1755.2002. 00356.x.
Penno G, Solini A, Bonora E, et al. Clinicalsignificance of nonalbuminuric renal impairment intype 2 diabetes. J Hypertens. Published online 2011. doi:10.1097/HJH.0b013e3283495cd6.
Thomas MC, MacIsaac RJ, Jerums G, et al.Nonalbuminuric renal impairment in type 2 diabeticpatients and in the general population (NationalEvaluation of the Frequency of Renal ImpairmentcO-existing with NIDDM [NEFRON] 11). DiabetesCare. Published online 2009. doi:10.2337/dc08-2186.
Retnakaran R, Cull CA, Thorne KI, Adler AI, HolmanRR. Risk factors for renal dysfunction in type 2diabetes: U.K. Prospective Diabetes Study 74. Diabetes.Published online 2006. doi:10.2337/db05-1620.
Caramori ML, Fioretto P, Mauer M. Low glomerularfiltration rate in normoalbuminuric type 1 diabeticpatients: An indicator of more advanced glomerularlesions. Diabetes. Published online 2003. doi:10.2337/diabetes.52.4.1036.
Kramer HJ, Nguyen QD, Curhan G, Hsu CY.Renal Insufficiency in the Absence of Albuminuriaand Retinopathy among Adults with Type 2 DiabetesMellitus. J Am Med Assoc. Published online 2003.doi:10.1001/jama.289.24.3273
Tsalamandris C, Allen TJ, Gilbert RE, et al. Progressivedecline in renal function in diabetic patients with andwithout albuminuria. Diabetes. Published online 1994.doi:10.2337/diab.43.5.649.
MacIsaac RJ, Jerums G. Diabetic kidney diseasewith and without albuminuria. Curr Opin NephrolHypertens. Published online 2011. doi:10.1097/MNH.0b013e3283456546.
Li XZ, He JC. An update: the role of Nephrin insideand outside the kidney. Sci China Life Sci. Publishedonline 2015. doi:10.1007/s11427-015-4844-1.
Ekinci EI, Jerums G, Skene A, et al. Renal structure innormoalbuminuric and albuminuric patients with type2 diabetes and impaired renal function. Diabetes Care.Published online 2013. doi:10.2337/dc12-2572.
Yagil C, Barak A, Ben-Dor D, et al. Nonproteinuricdiabetes-associated nephropathy in the cohen rat modelof type 2 diabetes. Diabetes. Published online 2005.doi:10.2337/diabetes.54.5.1487.
Osicka TM, Houlihan CA, Chan JG, Jerums G,Comper WD. Albuminuria in patients with type 1diabetes is directly linked to changes in the lysosomemediateddegradation of albumin during renalpassage. Diabetes. Published online 2000. doi:10.2337/diabetes.49.9.1579.
Pugliese G, Solini A, Zoppini G, et al. High prevalenceof advanced retinopathy in patients with type 2 diabetesfrom the Renal Insufficiency and CardiovascularEvents (RIACE) Italian Multicenter Study. DiabetesRes Clin Pract. Published online 2012. doi: 10.1016/j.diabres.2012.09.006.
Kramer CK, Leitão CB, Pinto LC, Silveiro SP, GrossJL, Canani LH. Clinical and laboratory profile ofpatients with type 2 diabetes with low glomerularfiltration rate and normoalbuminuria. Diabetes Care.Published online 2007. doi:10.2337/dc07-0387.
Rico JE. Enfermedad Renal Diabética. Nefrol basica 2Soc Nefrol. Published online 2018.
Johnson RJ, Rodriguez-Iturbe B. Rethinkingprogression of CKD as a process of punctuatedequilibrium. Nat Rev Nephrol. Published online 2018.doi:10.1038/s41581-018-0016-4.
Pugliese G, Penno G, Natali A, et al. Diabetic kidneydisease: new clinical and therapeutic issues. Jointposition statement of the Italian Diabetes Society andthe Italian Society of Nephrology on “The naturalhistory of diabetic kidney disease and treatment ofhyperglycemia in patients with. J Nephrol. Publishedonline 2020. doi:10.1007/s40620-019-00650-x.
Caramori ML, Fioretto P, Mauer M. Enhancingthe predictive value of urinary albumin for diabeticnephropathy. J Am Soc Nephrol. Published online 2006.doi:10.1681/ASN.2005101075.
Rico Fontalvo JE. Guía de práctica clínica parala enfermedad renal diabética. Rev Colomb Nefrol.2021;8(2). doi:10.22265/acnef.8.2.561.
Pilemann-Lyberg S, Hansen TW, Tofte N, et al. Uricacid is an independent risk factor for decline in kidneyfunction, cardiovascular events, and mortality inpatients with type 1 diabetes. Diabetes Care. Publishedonline 2019. doi:10.2337/dc18-2173.
Afkarian M, Polsky S, Parsa A, et al. Preventing EarlyRenal Loss in Diabetes (PERL) study: A randomizeddouble-blinded trial of allopurinoldrationale, design,and baseline data. Diabetes Care. Published online2019. doi:10.2337/dc19-0342.
Coca SG, Nadkarni GN, Huang Y, et al. Plasmabiomarkers and kidney function decline in early andestablished diabetic kidney disease. J Am Soc Nephrol.Published online 2017. doi:10.1681/ASN.2016101101.
Nadkarni GN, Rao V, Ismail-Beigi F, et al. Associationof urinary biomarkers of inflammation, injury, andfibrosis with renal function decline: The ACCORDtrial. Clin J Am Soc Nephrol. Published online 2016.doi:10.2215/CJN.12051115.
Sabbisetti VS, Waikar SS, Antoine DJ, et al. Bloodkidney injury molecule-1 is a biomarker of acute andchronic kidney injury and predicts progression toESRD in type I diabetes. J Am Soc Nephrol. Publishedonline 2014. doi:10.1681/ASN.2013070758.
Araki SI, Haneda M, Koya D, et al. Predictiveeffects of urinary liver-type fatty acid-binding proteinfor deteriorating renal function and incidence ofcardiovascular disease in type 2 diabetic patientswithout advanced nephropathy. Diabetes Care.Published online 2013. doi:10.2337/dc12-1298.
Klisic A, Kavaric N, Ninic A. Retinol-bindingprotein 4 versus albuminuria as predictors of estimatedglomerular filtration rate decline in patients with type2 diabetes. J Res Med Sci. Published online 2018. doi:10.4103/jrms.JRMS_893_17.
Araki SI, Haneda M, Koya D, et al. Associationbetween urinary type IV collagen level and deteriorationof renal function in type 2 diabetic patients withoutovert proteinuria. Diabetes Care. Published online2010. doi:10.2337/dc10-0199.
Rico Fontalvo JE, Daza Anedo R, Raad Sarabia M, etal. Proteoma urinario en la enfermedad renal diabética.Estado del arte. Rev Colomb Nefrol. Published online2021. doi:10.22265/acnef.8.3.546.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidneydisease: Challenges, progress, and possibilities. Clin JAm Soc Nephrol. Published online 2017. doi:10.2215/CJN.11491116.
Marso SP, Bain SC, Consoli A, et al. Semaglutideand cardiovascular outcomes in patients with type2 diabetes. N Engl J Med. Published online 2016.doi:10.1056/NEJMoa1607141.
Liraglutide and Renal Outcomes in Type 2 Diabetes.N Engl J Med. Published online 2017. doi:10.1056/nejmc1713042.
Gerstein HC, Colhoun HM, Dagenais GR, et al.Dulaglutide and cardiovascular outcomes in type 2diabetes (REWIND): a double-blind, randomisedplacebo-controlled trial. Lancet. Published online 2019.doi:10.1016/S0140-6736(19)31149-3.
Takahashi K, Nakamura A, Furusawa S, et al. Initial dippredicts renal protective effects after the administrationof sodium-glucose cotransporter 2 inhibitors in patientswith type 2 diabetes and chronic kidney disease withnormoalbuminuria. J Clin Transl Endocrinol. Publishedonline 2020. doi: 10.1016/j.jcte.2020.100244.
Heerspink HJL, Stefánsson BV, Correa-RotterR, Chertow GM, Greene T, Hou FF, Mann JFE,McMurray JJV, Lindberg M, Rossing P, Sjöström CD,Toto RD, Langkilde AM, Wheeler DC; DAPA-CKDTrial Committees and Investigators. Dapagliflozinin Patients with Chronic Kidney Disease. N Engl JMed. 2020 Oct 8;383(15): 1436-1446. Doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID:32970396.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, vonEynatten M, Mattheus M, Johansen OE, Woerle HJ,Broedl UC, Zinman B; EMPA-REG OUTCOMEInvestigators. Empagliflozin and Progression of KidneyDisease in Type 2 Diabetes. N Engl J Med. 2016 Jul28;375(4): 323-34. Doi: 10.1056/NEJMoa1515920.Epub 2016 Jun 14. PMID: 27299675.
Texto completo
Cómo citar este artículo
Artículos similares